Hypertriglyceridaemia — reduce-it with icosapent ethyl

Access through your institution Buy or subscribe Use of icosapent ethyl is associated with a reduction in triglyceride levels and ischaemic events, including cardiovascular death, according

to the results of the REDUCE-IT trial presented at the AHA Scientific Sessions. “The broad population of patients with elevated triglyceride [levels] we studied makes me believe that these

results are widely applicable to millions of patients around the world,” comments lead investigator, Deepak Bhatt. In the JELIS trial, eicosapentaenoic acid was shown to lower the risk of

major coronary events in a Japanese population with hypertriglyceridaemia. The REDUCE-IT trial was designed to test the effect of icosapent ethyl — a highly purified form of eicosapentaenoic

acid — on cardiovascular outcomes. The trial included a total of 8,179 patients with established cardiovascular disease or diabetes mellitus and other risk factors who had been receiving

statin therapy. Initial enrolment included patients who had a fasting triglyceride level of 135–499 mg/dl and an LDL-cholesterol level of 41–100 mg/dl, but as the study progressed, the

minimum triglyceride threshold was increased to 200 mg/dl. The baseline median levels of triglycerides and LDL-cholesterol were 216.0 mg/dl and 75.0 mg/dl, respectively. “The triglyceride

entry criteria are important because they are a signal of potential residual risk that is not being managed by statin treatment,” comments Robert Hegele, who was not involved in the study.

“There is no approved therapy for the residual risk in these patients.” This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12

print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be

subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

REFERENCES ORIGINAL ARTICLE * Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. _N. Engl. J. Med._ https://doi.org/10.1056/NEJMoa1812792 (2018)

Article  PubMed  PubMed Central  Google Scholar  FURTHER READING * Reiner, Ž. Hypertriglyceridaemia and risk of coronary artery disease. _Nat. Rev. Cardiol._ 14, 401–411 (2017) Article  CAS

  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Reviews Cardiology http://www.nature.com/nrcardio/ Gregory B. Lim Authors * Gregory B. Lim View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Gregory B. Lim. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Lim, G.B. Hypertriglyceridaemia — REDUCE-IT with icosapent ethyl. _Nat Rev Cardiol_ 16, 1 (2019). https://doi.org/10.1038/s41569-018-0129-2 Download citation *

Published: 27 November 2018 * Issue Date: January 2019 * DOI: https://doi.org/10.1038/s41569-018-0129-2 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative